Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Measurable residual disease (MRD) measured using multiparameter flow-cytometry (MFC) has proven to be an important prognostic biomarker in acute myeloid leukemia (AML). In addition, MRD is increasingly used to guide consolidation treatment towards a non-allogenic stem cell transplantation treatment...

Full description

Bibliographic Details
Main Authors: Jesse M. Tettero, Waleed K. W. Al-Badri, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Catharina H. M. J. van Elssen, Thomas Fischer, Bjorn T. Gjertsen, Gwendolyn N. Y. van Gorkom, Patrycja Gradowska, Marjolein J. E. Greuter, Laimonas Griskevicius, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Bob Löwenberg, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen, Jacqueline Cloos
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
measurable residual disease (MRD)
multiparameter flow cytometry (MFC)
prognostic value
earlier detection
guided therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.999822/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.999822/full

Similar Items